OpGen (NASDAQ:OPGN) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGNGet Rating) in a research note issued on Sunday. The firm set a “sell” rating on the medical research company’s stock.

Other equities research analysts have also issued reports about the stock. Alliance Global Partners reduced their target price on shares of OpGen from $4.35 to $3.00 in a report on Wednesday, January 12th. Zacks Investment Research cut shares of OpGen from a “hold” rating to a “sell” rating in a research report on Tuesday, April 5th.

NASDAQ:OPGN opened at $0.52 on Friday. OpGen has a 52 week low of $0.51 and a 52 week high of $3.72. The company has a quick ratio of 1.93, a current ratio of 2.00 and a debt-to-equity ratio of 0.17. The business’s 50-day simple moving average is $0.75 and its two-hundred day simple moving average is $1.11. The stock has a market cap of $24.35 million, a PE ratio of -0.44 and a beta of -0.74.

OpGen (NASDAQ:OPGNGet Rating) last announced its quarterly earnings data on Tuesday, March 29th. The medical research company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.19). OpGen had a negative net margin of 810.33% and a negative return on equity of 71.61%. The business had revenue of $1.43 million for the quarter, compared to analysts’ expectations of $1.40 million. During the same period in the prior year, the company posted ($0.35) EPS. Sell-side analysts anticipate that OpGen will post -0.62 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in OPGN. Arete Wealth Advisors LLC purchased a new position in OpGen during the fourth quarter worth approximately $54,000. Millennium Management LLC acquired a new stake in OpGen during the 2nd quarter valued at $80,000. Virtu Financial LLC grew its holdings in OpGen by 205.1% during the 4th quarter. Virtu Financial LLC now owns 83,227 shares of the medical research company’s stock worth $83,000 after acquiring an additional 55,946 shares in the last quarter. Citadel Advisors LLC grew its holdings in OpGen by 101.2% during the 4th quarter. Citadel Advisors LLC now owns 114,316 shares of the medical research company’s stock worth $115,000 after acquiring an additional 57,491 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in OpGen by 229.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 40,559 shares of the medical research company’s stock worth $117,000 after acquiring an additional 28,242 shares in the last quarter. 7.74% of the stock is currently owned by institutional investors and hedge funds.

OpGen Company Profile (Get Rating)

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.

Further Reading

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.